Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3
about
Real-Time Imaging of Interactions of Neutrophils with Cryptococcus neoformans Demonstrates a Crucial Role of Complement C5a-C5aR SignalingA role for LHC1 in higher order structure and complement binding of the Cryptococcus neoformans capsuleCryptococcal interactions with the host immune system.Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infectionThe absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans.Cryptococcus interactions with macrophages: evasion and manipulation of the phagosome by a fungal pathogen.Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformansConcurrent presentation of cryptococcal meningoencephalitis and systemic lupus erythematosus.Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophagesIn vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.THE ROLE OF SPECIFIC IgG AND COMPLEMENT IN COMBATING A PRIMARY MUCOSAL INFECTION OF THE GUT EPITHELIUM.New concepts in antibody-mediated immunity.IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.B cells and antibodies in the defense against Mycobacterium tuberculosis infectionMolecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.Anamnestic protective immunity to Bacillus anthracis is antibody mediated but independent of complement and Fc receptors.Formalin-inactivated Coxiella burnetii phase I vaccine-induced protection depends on B cells to produce protective IgM and IgG.Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.Adhesins and host serum factors drive Yop translocation by yersinia into professional phagocytes during animal infection.Striking a balance: fungal commensalism versus pathogenesisThe capsule of the fungal pathogen Cryptococcus neoformans.The intracellular life of Cryptococcus neoformans.Intravascular clearance of disseminating Cryptococcus neoformans in the brain can be improved by enhancing neutrophil recruitment in mice.Microevolution during serial mouse passage demonstrates FRE3 as a virulence adaptation gene in Cryptococcus neoformans.Yersinia pseudotuberculosis uses Ail and YadA to circumvent neutrophils by directing Yop translocation during lung infection.Host defenses against cryptococcosis.Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.The protective role of immunoglobulins in fungal infections and inflammation.Cryptococcal therapies and drug targets: the old, the new and the promising.The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus.Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax.The formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses.Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain.O antigen protects Bordetella parapertussis from complement.Virulence Factors as Targets for Anticryptococcal Therapy.Recent Advancements in Combinational Antifungal Therapy and Immunotherapy
P2860
Q27322596-26DB430B-231A-429A-B1FE-49CB91B1F291Q28538344-3C01CF1E-0A00-41FA-881E-B1D46ECABE9DQ30387948-7C16622E-016D-44AA-BF1C-6C644A9871B6Q33496734-598546B5-65C7-4194-882C-D2DA32610415Q33912345-2551A735-53AE-4FBF-8FA4-A50F56A8E37DQ34310010-C129FD30-BB67-4819-A272-4B1923161D44Q34680995-5B09F4D4-FAD5-4306-B59C-A8E6FAD0B8D5Q35031666-93A42190-9F5F-4FAE-AF7E-486A909BEE38Q35118828-C3D3FF87-49C7-4DCE-BD1B-E552B63639B6Q35186300-483B223F-ACB5-413D-AEE8-8A519DDE62A3Q35689463-4ED210B2-FFC9-459C-82DC-41358DD9DA84Q35869432-00530BCE-239E-4A3F-BC38-4290F2CF7732Q35926507-9975539F-E28F-4656-9F28-A5A915C5090EQ35952109-FC4CE111-57B2-4EA2-BE5F-97464BD0E31AQ36238031-33184D72-85DD-4D1F-8225-6953ACBE6727Q36456615-2CDD3B23-A27A-4701-A21E-743143F082CCQ36594024-EC7FFE21-83C8-40DF-9909-8E04F266751EQ36911430-78B18B5F-7D9B-477E-837B-DF278931B638Q36914682-99A710C3-E82D-45B6-95BA-0BF281DA1236Q36944708-83B89E10-668B-4645-A345-34A0F36CE0B1Q37092848-DA18581B-375C-45ED-B433-D9C6EF848686Q37337879-4F40897B-785E-4AE3-8D17-18B6D424F8F2Q37452401-8BE9BD2A-02B6-4421-A610-3A425FD1F40DQ37513520-CD919D87-DD1D-4DDC-95A8-3762A30C76A6Q37687813-DAA80C0F-AE21-45D8-9942-62CD35692896Q37695112-F68E003B-E355-4B50-AE49-6680E3E14FBEQ37943849-CCEA6EEA-A6D8-4B07-AC81-C50F25697BBBQ38011299-363D66E2-518A-477D-B6C1-F03D8D0FBF5DQ38268922-4B5EA1F5-508C-421A-AB0D-359432F10B6FQ38779568-4E8A9B10-9309-47F5-9677-0AA7E5D3F944Q39757189-11319339-1920-4528-8CB5-FE73C7C0A78AQ40312835-A944292D-0A06-4820-9738-3EF50EC25E44Q41071866-2880B2C7-1465-4175-9FEF-9F9527F1A7E4Q41809893-5D0C2F99-E5FE-4F22-82AE-2455C37C9868Q42587145-A962A9C9-A1DB-4678-AB5B-2ACC639345CEQ43112209-F13BF7AD-5BB5-4985-AB75-6BEC4C1D928AQ49612928-9FA550A8-9D8B-4C8F-BACB-BE34DB4DCADFQ57705351-8129B3BE-4C2B-4228-9CB3-1BF85FC4C416
P2860
Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunoglobulin G monoclonal an ...... ent in complement component C3
@ast
Immunoglobulin G monoclonal an ...... ent in complement component C3
@en
Immunoglobulin G monoclonal an ...... ent in complement component C3
@nl
type
label
Immunoglobulin G monoclonal an ...... ent in complement component C3
@ast
Immunoglobulin G monoclonal an ...... ent in complement component C3
@en
Immunoglobulin G monoclonal an ...... ent in complement component C3
@nl
prefLabel
Immunoglobulin G monoclonal an ...... ent in complement component C3
@ast
Immunoglobulin G monoclonal an ...... ent in complement component C3
@en
Immunoglobulin G monoclonal an ...... ent in complement component C3
@nl
P2093
P2860
P1476
Immunoglobulin G monoclonal an ...... ent in complement component C3
@en
P2093
Carlos Taborda
David O Beenhouwer
Marta Feldmesser
Matthew D Scharff
Michael C Carroll
Scott Shapiro
P2860
P304
P356
10.1128/IAI.70.5.2598-2604.2002
P407
P577
2002-05-01T00:00:00Z